Biology and therapy of immunoglobulin deposition diseases

Hematology/Oncology Clinics of North America

Volumn 11, Issue 1, 1997, Pages 89-110

  Dhodapkar, M V ^a   Merlini, G ^a   Solomon, A ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; IMMUNOGLOBULIN DEPOSITION; KIDNEY; KIDNEY AMYLOIDOSIS; KIDNEY FAILURE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PATHOGENESIS; PLASMA CELL; PRIORITY JOURNAL; REVIEW;

EID: 0030889391     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70417-2     Document Type: Article

References (109)

1. M. Abe T. Goto S.J. Kennel Production and immunodiagnostic applications of antihuman light chain monoclonal antibodies Am J Clin Pathol 100 1993 67
2. C.E. Alpers Fibrillary glomerulonephritis and immunotactoid glomerulopathy: Two entities, not one Am J Kidney Dis 22 1993 448
3. C. Aprile G. Marinone R. Saponaro Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin Eur J Nucl Med 22 1995 1393
4. P. Aucouturier A.A. Khamlichi G. Touchard Brief report: Heavy-chain deposition disease N Engl J Med 329 1993 1389
5. M.L. Baltz D. Caspi D.J. Evans Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits Clin Exp Immunol 66 1986 691
6. B. Barbieri F.C. Giuliani T. Bordoni Chemical and biological characterization of 4′-iodo-4′-deoxydoxorubicin Cancer Res 47 1987 4001
7. V. Bellotti G. Merlini E. Bucciarelli Relevance of class, molecular weight and isoelectric point in predicting human light chain amyloidogenicity Br J Haematol 74 1990 65
8. H. Bennhold Ein spezifishe amyloidfarbung mit Kongorot Muenchner Medizinische Wochenschrift 69 1922 1537
9. L. Benson A. Hemmingsson A. Ericsson Magnetic resonance imaging in primary amyloidosis Acta Radiol 28 1986 13
10. J. Buxbaum Aberrant immunoglobulin synthesis in light chain amyloidosis. Free light chain and light chain fragment production by human bone marrow cells in short-term tissue culture J Clin Invest 78 1986 798
11. J. Buxbaum Mechanisms of disease: Monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease Hematol Oncol Clin North Am 6 1992 323
12. J.N. Buxbaum J.V. Chuba G.C. Hellman Monoclonal immunoglobulin deposition disease: Light chain and heavy chain deposition diseases and their relation to light chain amyloidosis Ann Intern Med 112 1990 455
13. P. Camilleri N.J. Haskins Beta-Cyclodextrin interacts with the Alzheimer amyloid beta-A4 peptide FEBS Lett 341 1994 256
14. E.S. Cathcart AEF: An enigma wrapped in a mystery Amyloid: Int J Exp Clin Invest 2 1995 126
15. R.L. Comenzo E. Vosburgh D.L. Sarnacki High-dose melphalan with blood stem-cell support for AL amyloidosis Blood 86 suppl 1 1995 206a
16. L. Cueto-Garcia G.S. Reeder R.A. Kyle Echocardiographic findings in systemic amyloidosis: Spectrum of cardiac involvement and relation to survival J Am Coll Cardiol 6 1985 737
17. L. Denoroy S. Deret P. Aucouturier Overrepresentation of the VkIV subgroup in L chain deposition disease Immunol Lett 42 1994 63
18. M. Dhodapkar S. Jagannath D. Vesole Efficacy of pulse dexamethasone plus maintenance alpha interferon in primary systemic amyloidosis Blood 86 suppl 1 1995 442a
19. M. Eulitz D.T. Weiss A. Solomon Immunoglobulin heavy-chain-associated amyloidosis Proc Natl Acad Sci USA 87 1990 6542
20. R.H. Falk J.F. Plehn T. Deering Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis Am J Cardiol 59 1987 418
21. Fattori E. Della Rocca C. P. Costa Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice Blood 83 1994 2570
22. C. Faure B. Venin J.C. Bousquet Primary amyloidosis of the bones. MRI aspects J Radiol 76 1995 1025
23. G. Ferri M. Stopponi P. Iadarola Structural characterization of k II Inc, a new amyloid immunoglobulin Biochim Biophys Acta 995 1989 103
24. A. Fogo N. Quereshi R.G. Horn Morphologic and clinical features of fibrillary glomerulonephritis versus immunotactoid glomerulopathy Am J Kid Dis 22 1993 367
25. J. Frippiat S.C. Williams I.M. Tomlinson Organization of the human immunoglobulin lambda light-chain locus on chromosome 22q11.2 Hum Mol Genet 4 1995 983
26. G. Gallo F. Gon˜i F. Boctor Light chain cardiomyopathy. Structural analysis of the light chain tissue deposits Am J Pathol 148 1996 1397
27. G. Gallo M. Picken J. Buxbaum B. Frangione The spectrum of monoclonal immunoglobulin deposition disease associated with immunocytic dyscrasias Semin Hematol 26 1989 234
28. G. Gallo T. Wisniewski Choi-Miura N.-H. Potential role of apolipoprotein-E in fibrillogenesis Am J Pathol 145 1994 526
29. Ganeval D. Noe¨l L.-H. Preud'homme J.-L. Light-chain deposition disease: Its relation with AL-type amyloidosis Kidney Int 26 1984 1
30. M.A. Gertz R.A. Kyle Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis Arch Intern Med 150 1990 629
31. M.A. Gertz R.A. Kyle Primary systemic amyloidosis: A diagnostic primer Mayo Clin Proc 64 1989 505
32. M.A. Gertz R.A. Kyle Phase II trial of recombinant interferon alpha 2 in the treatment of primary systemic amyloidosis Am J Hematol 44 1993 125
33. M.A. Gertz R.A. Kyle P.R. Greipp Response rates and survival in primary systemic amyloidosis Blood 77 1991 257
34. M.A. Gertz R.A. Kyle P.R. Greipp Beta 2 microglobulin predicts survival in primary systemic amyloidosis Am J Med 89 1990 609
35. M.A. Gertz R.A. Kyle W.M. O'Fallon Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients Arch Intern Med 152 1992 2245
36. L. Gianni V. Bellotti M. Gianni New drug therapy for amyloidoses: Resorption of AL type deposits with 4′-iodo-4′ deoxydoxorubicin Blood 86 1995 855
37. G.G. Glenner Amyloid deposits and amyloidosis: The b-fibrilloses N Engl J Med 302 1283,1333 1980
38. J. Hardin S.L. MacLeod I. Grigorieva Interleukin-6 prevents dexamethasone induced myeloma cell death Blood 84 1994 3063
39. 123 labelled serum amyloid P component N Engl J Med 323 1990 508
40. P.N. Hawkins M.J. Myers A.A. Epentos Specific localization and imaging of amyloid deposits in vivo using I123 labelled serum amyloid P component J Exp Med 167 1988 903
41. P.N. Hawkins S. Richardson J.E. MacSweeney Scintigraphic quantification and serial monitoring of human visceral deposits provide evidence for turnover and regression Q J Med 86 1993 365
42. R.L. Heilman J.A. Velosa K.E. Holley Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease Am J Kidney Dis 20 1992 34
43. L.R. Helms R. Wetzel Specificity of abnormal assembly in immunoglobulin light chain deposition disease and amyloidosis J Mol Biol 257 1996 77
44. L.M. Hendershot Immunoglobulin heavy chain and binding protein complexes are dissociated in vivo by light chain addition J Cell Biol 111 1990 829
45. G.A. Herrera P.W. Sanders B.V. Reddy Ultrastructural immunolabeling: A unique diagnostic tool in monoclonal light chain–related renal diseases Ultrastruct Pathol 18 1994 401
46. G.A. Herrera J.J. Shultz Soong S.-J. P.W. Sanders Growth factors in monoclonal light-chain–related renal diseases Hum Pathol 25 1994 883
47. Z. Huang P.W. Sanders Biochemical interaction between Tamm-Horsfall glycoprotein and Ig light chains in the pathogenesis of cast nephropathy Lab Invest 73 1995 810
48. M.R. Hurle L.R. Helms L. Li A role for destabilizing amino acid replacements in light-chain amyloidosis Proc Natl Acad Sci USA 91 1994 5446
49. S. Jagannath D. Vesole L. Glenn Low risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support Blood 80 1992 1666
50. Jarrett J.T. Lansbury P.T. Jr Amyloid fibril formation requires a chemically discriminating nucleation event: Studies of an amyloidogenic sequence from the bacterial protein OsmB Biochemistry 31 1992 12345
51. A.A. Khamlichi A. Rocca G. Touchard Role of light chain variable region in myeloma with light chain deposition disease: Evidence from an experimental model Blood 86 1995 3955
52. C.J. Kirkpatrick A. Curry J. Galle Systemic kappa light chain deposition and amyloidosis in multiple myeloma: Novel morphological observations Histopathology 10 1986 1065
53. R. Kisilevsky L.J. Lemieux P.E. Fraser Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: Implication for Alzheimer's disease Nature Med 1 1995 143
54. Klafki H.-W. H.D. Kratzin A.I. Pick Complete amino acid sequence determinations demonstrate identity of the urinary Bence Jones protein (BJP-DIA) and the amyloid fibril protein (AL-DIA) in a case of AL-amyloidosis Biochemistry 31 1992 3265
55. A.L. Klein L.K. Hatle C.P. Taliercio Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis J Am Coll Cardiol 16 1990 1135
56. R. Klein R. Jaenichen H.G. Zachau Expressed human immunoglobulin k genes and their hypermutation Eur J Immunol 23 1993 3248
57. S.M. Korbet M.M. Schwartz E.J. Lewis The fibrillary glomerulopathies Am J Kidney Dis 23 1994 751
58. R.A. Kyle M.A. Gertz Primary systemic amyloidosis: Clinical and laboratory features in 474 cases Semin Hematol 32 1995 45
59. R.A. Kyle P.R. Greipp J.P. Garton M.A. Gertz Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine Am J Med 80 1986 413
60. R.A. Kyle P.R. Greipp W.M. O'Fallon Primary systemic amyloidosis: Multivariate analysis for prognostic factors in 168 cases Blood 68 1986 220
61. R.A. Kyle R.D. Wagoner K.E. Holley Primary systemic amyloidosis: Resolution of the nephrotic syndrome with melphalan and prednisone Arch Intern Med 142 1982 1445
62. A. Lorenzo B.A. Yankner Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red Proc Natl Acad Sci USA 91 1994 12243
63. Mariette X. Clauvel J.-P. Brouet J.-C. Lokhorst H.M. L.F. Verdonck Intensive therapy in AL amyloidosis and light-chain deposition disease [letter] Ann Intern Med 123 1995 553
64. R.G. Masson H.G. Rennke M.N. Gottlieb Pulmonary hemorrhage in a patient with fibrillary glomerulonephritis N Engl J Med 326 1992 36
65. G. Merlini Treatment of primary amyloidosis Semin Hematol 32 1995 60
66. G. Merlini E. Ascari N. Amboldi Interaction of the anthracycline 4′-iodo-4′- deoxydoxorubicin with amyloid fibrils: Inhibition of fibrillogenesis Proc Natl Acad Sci USA 92 1995 2959
67. P. Moreau N. Milpied de Faucal P. High-dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement Blood 87 1996 3063
68. E.A. Myatt F.A. Westholm D.T. Weiss Pathogenic potential of human monoclonal immunoglobulin light chains: Relationship of in vitro aggregation to in vivo organ deposition Proc Natl Acad Sci USA 91 1994 3034
69. S.T. Nelson M. Lyon J.T. Gallagher Isolation and characterization of the integral glycosaminoglycan constituents of human amyloid A and monoclonal light-chain amyloid fibrils Biochem J 275 1991 67
70. S. Ozaki M. Abe D. Wolfenbarger Preferential expression of human λ-light-chain variable-region subgroups in multiple myeloma, AL amyloidosis, and Waldenstro¨m's macroglobulinemia Clin Immunol Immunopathol 71 1994 183
71. E. Pascali Diagnosis and treatment of primary amyloidosis Crit Rev Oncol Hematol 19 1995 149
72. A. Pasternack J. Ahonen B. Kuhlback Renal transplantation in 45 patients with amyloidosis Transplantation 42 1986 598
73. M.B. Pepys T.W. Rademacher S. Amatayakul-Chantler Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure Proc Natl Acad Sci USA 91 1994 5602
74. V. Perfetti P. Garini Colli Vignarelli M. Diagnostic approach to and follow-up of difficult cases of AL amyloidosis Haematologica 80 1995 409
75. C. Pozzi G.B. Fogazzi G. Banfi Renal disease and patient survival in light chain deposition disease Clin Nephrol 43 1995 281
76. J.L. Preud'homme P. Aucouturier G. Touchard Monoclonal immunoglobulin deposition disease (Randall type). Relationship with structural abnormalities of immunoglobulin chains Kidney Int 46 1994 965
77. J.L. Preud'homme D. Ganeval J.P. Gru¨nfeld Immunoglobulin synthesis in primary and myeloma amyloidosis Clin Exp Immunol 73 1988 389
78. R.E. Randall W.C. Williamson F. Mullinax Manifestations of systemic light chain deposition Am J Med 60 1976 293
79. A. Rocca A.A. Khamlichi G. Touchard Sequences of VkI subgroup light chains in Fanconi's syndrome. Light chain V region gene usage restriction and peculiarities in myeloma-associated Fanconi's syndrome J Immunol 155 1995 3245
80. P.W. Sanders G.A. Herrera Monoclonal immunoglobulin light chain related renal diseases Semin Nephrol 13 1993 324
81. P.W. Sanders B.B. Booker Pathobiology of cast nephropathy from human Bence Jones proteins J Clin Invest 89 1992 630
82. P.W. Sanders G.A. Herrera A. Chen Differential nephrotoxicity of low molecular weight proteins including Bence Jones proteins in the perfused rat nephron in vivo J Clin Invest 82 1988 2086
83. M. Schiffer Molecular anatomy and the pathological expression of antibody light chains Am J Pathol 148 1996 1339
84. M.M. Silver S.A. Hearn J.C. Walton Immunogold quantitation of immunoglobulin light chains in renal amyloidosis and kappa light chain nephropathy Am J Pathol 136 1990 997
85. M. Skinner J.J. Anderson R. Simms Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, colchicine versus colchicine alone Am J Med 100 1996 290
86. A.D. Snow J. Willner R. Kisilevsky Sulphated glycosaminoglycans: A common constituent of all amyloid? Lab Invest 56 1987 120
87. A. Solomon Clinical implications of monoclonal light chains Semin Oncol 13 1986 341
88. A. Solomon Light chains of immunoglobulins: Structural-genetic correlates Blood 68 1986 603
89. A. Solomon C.L. McLaughlin Bence Jones proteins and light chains of immunoglobulins. I. Formation and characterization of amino-terminal (variant) and carboxyl-terminal (constant) halves J Biol Chem 244 1969 3393
90. A. Solomon D.T. Weiss Protein and host factors implicated in the pathogenesis of light-chain amyloidosis Amyloid: Int J Exp Clin Invest 2 1995 269
91. A. Solomon D.T. Weiss Structural and functional properties of human λ light-chain variable-region subgroups Clinical Diagnostic Laboratory Immunology 2 1995 387
92. VI subgroup of human light chains with amyloidosis AL(1) J Clin Invest 70 1982 453
93. A. Solomon D.T. Weiss A.A. Kattine Nephrotoxic potential of Bence Jones proteins N Engl J Med 324 1991 1845
94. A. Solomon D.T. Weiss C. Murphy Primary amyloidosis associated with a novel heavy-chain fragment (AH amyloidosis) Am J Hematol 45 1994 171
95. A. Solomon D.T. Weiss M.B. Pepys Induction in mice of human light-chain–associated amyloidosis Am J Pathol 140 1992 629
96. A. Solomon D.T. Weiss T.K. Williams Experimental model of human light-chain–associated disease Curr Top Microbiol Immunol 182 1992 261
97. T. Stenstad J.H. Magnus G. Husby S.O. Kolset Purification of amyloid-associated heparan sulphate proteoglycans and galactosaminoglycan free chains from human tissues Scand J Immunol 37 1993 227
98. F.J. Stevens E.A. Myatt Chang C.-H. A molecular model for self-assembly of amyloid fibrils: Immunoglobulin light chains Biochemistry 34 1995 10697
99. F.J. Stevens A. Solomon M. Schiffer Bence Jones proteins: A powerful tool for the fundamental study of protein chemistry and pathophysiology Biochemistry 30 1991 6803
100. E.H. Strøom G.B. Fogazzi G. Banfi Light chain deposition disease of the kidney. Morphological aspects in 24 patients Virchows Arch 425 1994 271
101. Y.M. Tagouri P.W. Sanders M.M. Picken In vitro AL-amyloid formation by rat and human mesangial cells Lab Invest 74 1996 290
102. H. Tanaka O. Tanabe K. Iwato Sensitive inhibitory effect of interferon α on M protein excretion of human multiple myeloma cell lines Blood 74 1989 1718
103. G.A. Tennent L.B. Lovat M.B. Pepys Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis Proc Natl Acad Sci USA 92 1995 4299
104. L.O. Tjernberg J. Na¨slund F. Lindqvist Arrest of β amyloid fibril formation by a pentapeptide ligand J Biol Chem 271 1996 8545
105. T. Tomiyama S. Asano Y. Suwa Rifampicin prevents the aggregation and neurotoxicity of amyloid β protein in vitro Biochem Biophys Res Commun 204 1994 76
106. G. Tricot D.A. Alberts C. Johnson Safety of autotransplants with high dose melphalan in renal failure: A pharmacokinetic and toxicity study Clin Cancer Res 2 1996 947
107. van Buren M. R.J. Hene´ L.F. Verdonck Clinical remission after syngeneic bone marrow transplantation in a patient with AL amyloidosis Ann Intern Med 122 1995 508
108. WHO-IUIS subcommittee Nomenclature of amyloid and amyloidoses Bull WHO 71 1993 105
109. P. Wilkins-Stevens R. Raffen D.K. Hanson Recombinant immunoglobulin variable domains generated from synthetic genes provide a system for in vitro characterization of light-chain amyloid proteins Protein Science 4 1995 421